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thus force tumor cells with supernumerary centrosomes to
undergo multipolar mitoses and consequently apoptosis.
Results: This approach led to the identification of several sub-
stances which are currently characterized in more detail. One of
these substances is the well-known antifungal drug griseofulvin,
which, in addition to its inhibition of centrosomal clustering
described here, has recently been shown to suppress microtubule
dynamic instability.
Conclusion: Taken together, this screening may help identify
new potential anti-cancer drugs.
doi:10.1016/j.ejcsup.2006.04.106
P47. RADIOPROTECTION OF NORMAL TISSUE CELLS BY
TRANSFER OF THE HUMAN SUPEROXIDE-DISMUTASE GENE
M.R. Veldwijka,b, C. Herskinda, S. Laufsb, W.J. Zellerb, S. Fruehaufc,
F. Wenza. aDepartment of Radiation Oncology, University of Heidelberg,
Mannheim, Germany; bGerman Cancer Research Center (E120),
Heidelberg, Germany; cDepartment of Internal Medicine V, University
of Heidelberg, Heidelberg, Germany.
Background: Protection of normal tissue against radiation-
induced damage would increase the therapeutic ratio of
radiotherapy. A promising strategy for this approach is gene
therapy-mediated overexpression of copper–zinc (CuZnSOD)
and manganese superoxide-dismutase (MnSOD). Recombinant
adeno-associated virus 2 (rAAV2) are attractive vectors owing
to their ability to infect non-dividing cells and a very low risk
of insertional mutagenesis. The purpose was to test the radio-
modulating effects of SOD on human primary lung fibroblasts
(HPLF).
Methods: Low passage HPLF (MRC5) cells were transduced with
the rAAV2-SOD vectors, harvested on day 3, irradiated (1–8 Gy)
and analysed using FACS, Western blot, SOD-activity and colony
formation assays.
Results: High transduction rates were obtained with >80% of the
HPLF cells expressing the respective SOD. Compared to transduc-
tion controls, CuZnSOD did not exhibit any radioprotective
effects, whereas for MnSOD-transduced HPLF an increase of
approximately 30% in the survival of colony-forming cells was
observed (1–4 Gy).
Conclusion: An increase in clonogenic survival (1.3-fold) of HPLF
cells after transfer of MnSOD and subsequent irradiation was
shown. Earlier, we have shown lack of protection in tumour cells
(HeLa), thus supporting that MnSOD may increase the therapeutic
ratio. rAAV2 vectors are promising tools for the delivery of radio-
protective genes in normal tissue such as the lung for pulmonary
or intestine cells for prostate irradiation.
doi:10.1016/j.ejcsup.2006.04.107
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Background: The normal development and functioning of the
prostate gland, as well as its benign and neoplastic growth is
dependent of androgen. Previous studies with Gonadotrophin
Realeasing Hormone (GnRH/LHRH) vaccines, have shown the use-
fulness of immunization against this hormone in prostate and
breast cancer.
Methods: In this work we have designed a vaccine candidate
called GnRHm1-TT based on a completely synthetic immunogen.
The peptide was formulated as a white semiviscous water in oil
preparation and injected to animals.
Results: In healthy animals, this vaccine candidate showed to
be very immunogenic, resulting in high anti-GnRH antibodies
titers, testosterone reduction and significant decrease of the
prostate and testicle weight. In tumor implanted rats the
vaccine candidate had demonstrated to produce significant
tumor growth inhibition of Dunning R3327-H androgen respon-
sive prostate tumor in rats P = 0.025 and survival increase,
P = 0.001.
Conclusion: GnRHm1-TT have demonstrated to be highly immu-
nogenic and safe, causing prostate and testicle atrophy and sig-
nificantly tumor growth inhibition. These results make our
vaccine candidate useful as an effective androgen deprivation
therapy, and possible application to prostate cancer and other
hormone-dependent malignancies therapy.
doi:10.1016/j.ejcsup.2006.04.108
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Background: Beside their use as anti resorptive drug, bisphos-
phonates are well known to stimulate cd T cells and to have direct
effects on tumor growth.
Methods: We determined the direct cytotoxic effect of pamidro-
nate and zoledronic acid, the induction of apoptosis and their
anti-metastatic potential. Next, we analyzed how bisphospho-
nates act on cd T cells propagated with our recently published
protocol. The susceptibility of pancreatic carcinoma cells pre-
treated with bisphosphonates against cd T cells was tested in
cytotoxicity assays and the subgroup involved in killing was
investigated.
